Literature DB >> 31773132

Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection.

Andrew G Flynn1,2, Kaylynn Aiona3, Michelle K Haas2,3, Randall Reves2, Robert Belknap2,3.   

Abstract

Although rare, subclinical tuberculosis disease can be missed during evaluations for latent tuberculosis infection, and can manifest with symptoms during latent tuberculosis treatment. Among over 8000 patients treated for latent tuberculosis we found no evidence of acquired drug resistance, underscoring the safety of rifampin monotherapy for latent tuberculosis.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  drug-resistant tuberculosis; isoniazid; paradoxical reaction; rifampin

Year:  2020        PMID： 31773132     DOI： 10.1093/cid/ciz1157

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  3 in total

1.  Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report.

Authors:  Denise Utami Putri; Chih-Hsin Lee; Tsung-Lun Li; Tai-Hua Chan; Cheng-Hui Wang; Ruwen Jou; Ming-Chih Yu; Yi-Hsien Lin
Journal:  Infect Drug Resist       Date:  2021-04-20       Impact factor: 4.003

2.  Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium tuberculosis (MTB)-induced immune response: Findings from PRACHITi, a cohort study in Pune, India.

Authors:  Ramesh Bhosale; Mallika Alexander; Prasad Deshpande; Vandana Kulkarni; Nikhil Gupte; Amita Gupta; Jyoti Mathad
Journal:  Int J Infect Dis       Date:  2021-09-10       Impact factor: 3.623

3.  Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.

Authors:  Emily A Kendall; Hamidah Hussain; Amber Kunkel; Rachel W Kubiak; Anete Trajman; Richard Menzies; Paul K Drain
Journal:  BMC Med       Date:  2021-12-14       Impact factor: 11.150
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.